DNB Asset Management AS increased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 10.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,215 shares of the medical instruments supplier’s stock after acquiring an additional 3,516 shares during the quarter. DNB Asset Management AS’s holdings in Becton Dickinson and were worth $8,665,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Wealth Quarterback LLC acquired a new position in shares of Becton Dickinson and during the fourth quarter valued at $7,588,711,000. State Street Corp lifted its stake in shares of Becton Dickinson and by 0.3% during the first quarter. State Street Corp now owns 11,490,473 shares of the medical instruments supplier’s stock valued at $2,640,166,000 after acquiring an additional 39,890 shares during the period. Wellington Management Group LLP lifted its stake in Becton Dickinson and by 225.4% in the first quarter. Wellington Management Group LLP now owns 8,473,220 shares of the medical instruments supplier’s stock valued at $1,946,892,000 after buying an additional 5,869,236 shares during the period. Morgan Stanley lifted its stake in Becton Dickinson and by 1.0% in the first quarter. Morgan Stanley now owns 5,901,391 shares of the medical instruments supplier’s stock valued at $1,355,965,000 after buying an additional 55,633 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in Becton Dickinson and by 27.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 4,086,572 shares of the medical instruments supplier’s stock valued at $938,970,000 after buying an additional 885,564 shares during the period. 85.78% of the stock is currently owned by institutional investors and hedge funds.
Shares of Becton Dickinson and stock opened at $252.73 on Thursday. Becton Dickinson and Co has a 1 year low of $197.75 and a 1 year high of $286.72. The business has a 50-day moving average of $239.72 and a two-hundred day moving average of $251.53. The company has a market capitalization of $68.17 billion, a P/E ratio of 76.12, a price-to-earnings-growth ratio of 3.33 and a beta of 0.93. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.98 and a quick ratio of 0.66.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th were issued a dividend of $0.79 per share. The ex-dividend date was Monday, June 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.25%. Becton Dickinson and’s payout ratio is presently 27.05%.
Several research firms have weighed in on BDX. Raymond James cut their target price on Becton Dickinson and from $290.00 to $265.00 and set an “outperform” rating on the stock in a research note on Thursday, June 25th. Wells Fargo & Co reissued a “buy” rating on shares of Becton Dickinson and in a research note on Friday, May 8th. UBS Group increased their target price on Becton Dickinson and from $260.00 to $265.00 and gave the company a “neutral” rating in a research note on Friday, May 8th. Goldman Sachs Group began coverage on Becton Dickinson and in a research note on Sunday, May 31st. They issued a “buy” rating and a $278.00 target price on the stock. Finally, Barclays raised Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $300.00 target price on the stock in a research note on Thursday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $274.13.
In related news, EVP Patrick Kaltenbach sold 1,049 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $243.20, for a total transaction of $255,116.80. Following the completion of the transaction, the executive vice president now directly owns 12,661 shares in the company, valued at $3,079,155.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.12% of the stock is currently owned by company insiders.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Why is momentum important to successful trading?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.